Tijdschrift voor psychiatrie · 2025
[Liothyronine augmentation in depression].
СтатьяОбзорАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Post A, Hoogeveen J H
Аннотация
BACKGROUND: The revised Dutch Multidisciplinary Guideline for Depression recommends liothyronine augmentation to selective serotonin reuptake inhibitors (SSRIs) as one of several third-line treatment options for moderate to severe depression, the others being lithium and atypical antipsychotics. The guideline refers to two network meta-analyses demonstrating efficacy.
AIM: To evaluate the evidence for efficacy of augmentation to SSRIs in depression.
METHOD: A PubMed and Cochrane Central search was conducted for controlled trials investigating added to an SSRI.
RESULTS: Seven studies were identified, three assessing augmentation and four examining co-initiation. Among the augmentation studies, only one was placebo-controlled and found no significant effect. Of the two active-controlled trials, one open-label study suggested better efficacy than lithium, while the other did not specify whether or was used (dose suggested) and showed similar efficacy to other augmentation options. The co-initiation trials reported conflicting results, ranging from better outcomes with to no difference or trend toward worse outcomes.
CONCLUSION: The efficacy of augmentation to an SSRI is not yet sufficiently established. Network meta-analyses are based primarily on active-controlled studies. Given the potential role of a long-term, placebo-controlled trial is needed to clarify the effectiveness of augmentation to an SSRI.
AIM: To evaluate the evidence for efficacy of augmentation to SSRIs in depression.
METHOD: A PubMed and Cochrane Central search was conducted for controlled trials investigating added to an SSRI.
RESULTS: Seven studies were identified, three assessing augmentation and four examining co-initiation. Among the augmentation studies, only one was placebo-controlled and found no significant effect. Of the two active-controlled trials, one open-label study suggested better efficacy than lithium, while the other did not specify whether or was used (dose suggested) and showed similar efficacy to other augmentation options. The co-initiation trials reported conflicting results, ranging from better outcomes with to no difference or trend toward worse outcomes.
CONCLUSION: The efficacy of augmentation to an SSRI is not yet sufficiently established. Network meta-analyses are based primarily on active-controlled studies. Given the potential role of a long-term, placebo-controlled trial is needed to clarify the effectiveness of augmentation to an SSRI.